A comparison of two primary care trials on tennis elbow: issues of external validity by Smidt, N. et al.
EXTENDED REPORT
A comparison of two primary care trials on tennis
elbow: issues of external validity
N Smidt, M Lewis, E M Hay, D A W M Van der Windt, L M Bouter, P Croft
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Dr Nynke Smidt, Institute
for Research in Extramural
Medicine, VU University
Medical Centre, Van der
Boechorststraat 7, 1081 BT
Amsterdam, Netherlands;
n.smidt@vumc.nl
Accepted 21 March 2005
Published Online First
30 March 2005
. . . . . . . . . . . . . . . . . . . . . . .
Ann Rheum Dis 2005;64:1406–1409. doi: 10.1136/ard.2004.029363
Objective: To assess clinical heterogeneity across two studies with respect to study population,
interventions, and outcome measures, and to evaluate the influence of these sources of heterogeneity
on the results of the studies.
Methods: The individual patient data were used from two randomised controlled trials investigating the
effectiveness of conservative treatments in patients with tennis elbow in primary care. Patients were
allocated at random to treatment with steroid injection, wait and see policy, non-steroidal anti-
inflammatory drugs, placebo tablets, or physiotherapy. Outcome measures included severity of the main
complaint, inconvenience of the elbow complaints, pain during the day, elbow disability, pain-free grip
strength, and global improvement. All outcomes were assessed at 1, 6, and 12 months after
randomisation.
Results: The two study populations were similar with respect to age, sex, comorbid neck/shoulder
complaints, and baseline scores for the severity of pain. However, significant differences were observed
for employment status, duration of elbow complaints, dominant side affected, previous history of elbow
complaints, and use of analgesics. Local injections differed between the two studies with respect to volume,
number, and steroid preparation. However, after 1, 6, and 12 months, the treatment effects of steroid
injections were very similar between the study populations.
Conclusions: Despite large differences in study population at baseline, the responses to steroid injections
were remarkably similar. Also the responses to other conservative interventions and the placebo treatment
were very consistent, suggesting a uniform course of a tennis elbow and a lack of influence of clinical
heterogeneity.
L
ateral epicondylalgia (tennis elbow) is a common
musculoskeletal problem. The incidence is estimated to
be 4–7 per 1000 patients per year in general practice,1 and
between 1% and 3% per year in the adult general popula-
tion.2–5 Recently, Assendelft et al summarised the available
evidence on the effectiveness of various treatment options for
lateral epicondylalgia.6 They concluded that topical non-
steroidal anti-inflammatory drugs (topical NSAIDs) are
effective for short term pain relief, and that oral NSAIDs
are likely to be beneficial. Limited evidence was found for the
short term effectiveness of steroid injections compared with
placebo, local anaesthetic, elbow strapping, or physiotherapy.
Although the randomised controlled trial (RCT) is the gold
standard for evaluating the effectiveness of interventions, it
is always open to question whether the results can be
generalised to other populations.
We compared two large pragmatic randomised controlled
trials in primary care investigating conservative treatments
for lateral epicondylalgia that were remarkably similar in
their outcome measures, interventions, and study popula-
tions.7 8 To investigate the generalisability of the results of
these RCTs concerning the effectiveness of conservative
treatments for lateral epicondylalgia,7 8 we determined the
clinical heterogeneity across the two studies for study
population, interventions, and outcome measures, and
evaluated the influence of these sources of heterogeneity on
the results of the studies.
METHODS
One RCT was carried out by Hay et al and compared the
effectiveness of local injection of 20 mg methylprednisolone
plus lignocaine (lidocaine), naproxen 500 mg twice daily for
two weeks, and placebo tablets in 164 patients with a new
episode of lateral epicondylalgia in North Staffordshire and
South Cheshire, United Kingdom.7
The second RCT was carried out in Amsterdam and its
vicinity in the Netherlands by Smidt et al.8 In this study, 185
patients with a new episode of lateral epicondylalgia were
allocated either to a local injection of 10 mg triamcinolone
acetonide and lignocaine, physiotherapy, or a wait and see
policy of ergonomic advice and pain medication.8
Study population
In both studies, consecutive patients who consulted their
general practitioner (GP) for elbow pain were eligible for
participation. The following inclusion criteria were applied in
both studies: clinical diagnosis of lateral epicondylalgia; age
between 18 and 70 years; and ability to fill in questionnaires
and give informed consent.
Exclusion criteria in both studies included the following:
contraindications to the treatments evaluated; previous
surgery of the elbow; congenital or acquired deformities of
the elbow; presence of signs and symptoms suggesting some
other cause of lateral elbow pain (for example, cervical
radiculopathy); and systemic musculoskeletal or neurological
disorders. However, Hay et al7 excluded patients who had
consulted their GP for their elbow pain during the preceding
12 months, whereas Smidt et al8 excluded patients who had
been treated with physiotherapy or injection in the previous
six months, patients with bilateral elbow complaints, and
those with symptoms of less than six weeks’ duration.
In both studies, patient characteristics and potential
prognostic factors were recorded by a research nurse at the
Abbreviations: NSAID, non-steroidal anti-inflammatory drug; RCT,
randomised controlled trial
1406
www.annrheumdis.com
initial visit before randomisation. Demographic and clinical
characteristics included age, sex, employment status, dura-
tion of the elbow complaints, presence of neck or shoulder
pain, previous elbow complaints, and use of analgesics. The
patients were also asked what they thought was the cause of
their elbow complaint.
Outcome measures
Both studies assessed the following:
N the severity of the main complaint;
N inconvenience of the elbow complaints;
N pain during the day;
N elbow disability;
N pain-free grip strength at baseline and during follow up at
1, 6, and 12 months.
For three of these outcome measures, minor differences
were found between the scales used in the two studies:
severity of the main complaint, inconvenience of the elbow
complaints, and pain during the day. Hay et al7 used a 10
point Likert scale whereas Smidt et al8 used an 11 point Likert
scale. Also, different versions of the Pain-free Function
Questionnaire9 were used to assess elbow disability: Hay et al7
used the eight item tool with binary response options
whereas Smidt et al8 used the 10 item tool including five
point Likert options. To standardise scores across the two
studies, all outcome measurements were transformed to 0 to
100 scales, where 100 indicates maximum severity.
The two studies used different instruments for the
measurement of grip strength (hand held dynamometer by
Hay et al7; Jamar hand dynamometer by Smidt et al8), and so
for comparison purposes, the ratio of grip strength in the
involved to the uninvolved arm was calculated and multi-
plied by 100 (a higher score indicates better grip strength).
General improvement was measured in both studies
directly after the intervention period. However, Hay et al7
used a five point Likert scale (complete recovered, improved,
no change, worse, much worse), whereas Smidt et al8 used a
six point Likert scale (completely recovered, much improved,
improved, no change, worse, much worse). For the computa-
tion of success rates, patients who rated themselves
‘‘completely recovered’’, ‘‘much improved’’, or ‘‘improved’’
were counted as successes.
Treatments
In the study of Hay et al, 53 patients were treated with a
steroid injection, 53 received naproxen, and 58 received
placebo tablets.7 In the study of Smidt et al, 64 patients were
allocated to physiotherapy treatment, 62 received a steroid
injection, and 59 were treated according to a wait and see
policy.8
Statistical analysis
The data analysis was based on the individual patient data
from both RCTs and was carried out using SPSS.10 Descriptive
statistics were used to analyse differences in patient
characteristics and outcome measures between the two study
populations, and describe the course of symptoms. The
Student t test was used for ordinal and continuous outcomes
and the x2 test for dichotomous outcomes.
To compare treatment effects between the two trials, the
following interventions were included: injection versus
NSAID or placebo (NSAID and placebo had similar effect)7;
Table 1 Patient characteristics at baseline*
Hay et al
(n = 164)
Smidt et al
(n = 185)
Difference between
studies (95% CI)
Sociodemographic characteristics
Age (years) (mean (SD)) 48 (9) 48 (10) 0.2 (22 to 2)
Female 78 (48%) 93 (50%) 22.7 (213 to 8)
Employment status
manual worker 73 (45%) 46 (25%) 19.6 (10 to 30)
non-manual worker 51 (31%) 77 (42%) 210.5 (221 to 20.5)
unemployed 40 (24%) 62 (34%) 29.1 (219 to 0.3)
Clinical characteristics
Duration of elbow complaints (weeks) (mean (SD)) 12 (15) 18 (27) 25.4 (210 to 21)
One elbow affected only 149 (91%) 185 (100%) 29.1 ( – )
Dominant side affected 100 (63%) 145 (78%) 215.1 (225 to 26)
Patients’ attributed causes of elbow complaints:
unexpected movement – 4 (2%) –
overuse, unusual activities 24 (15%) 45 (24%) 29.7 (218 to 22)
overuse, usual activities 33 (20%) 59 (32%) 211.8 (221 to 23)
accident 17 (10%) 3 (2%) 8.7 (4 to 14)
sport injury 12 (7%) 21 (11%) 24.0 (210 to 2)
other – 3 (2%) –
cause unknown 78 (48%) 50 (27%) 20.5 (11 to 31)
Concomitant neck or shoulder pain 56 (34%) 58 (31%) 2.8 (27 to 13)
Previous elbow complaints 32 (20%) 58 (31%) 211.8 (221 to 23)
Analgesics in previous 48 hours 118 (72%) 16 (9%) 63.3 (55 to 71)
Baseline measures of pain and function`
Severity of main complaint (mean (SD)) 59.3 (27.3) 67.4 (20.4) 28.1 (213 to 23)
Inconvenience of elbow complaints (mean (SD)) 39.4 (24.1) 67.5 (23.9) 228.1 (233 to 223)
Pain during the day (mean (SD)) 56.3 (24.2) 54.3 (21.1) 2.0 (23 to 7)
Pain-free grip strength (mean (SD)) 65.3 (23.4) 33.9 (21.6) 31.4 (27 to 36)
Elbow disability (mean (SD)) 78.6 (22.3) 48.2 (16.9) 30.4 (26 to 35)
*Values are n (%) unless specified.
Difference is mean difference (in percentages of mean scores) between the two studies and 95% confidence
intervals (CI).
`Mean differences (95% confidence interval) after adjustment for sociodemographic and clinical characteristics
(linear regression analyses) were as follows: severity of main complaint 216.3 (223.0 to 29.5); inconvenience of
elbow complaints 236.5 (243.5 to 229.5); pain during the day 26.0 (212.5 to 0.4); pain-free grip strength
34.9 (28.4 to 41.3); elbow disability 28.1 (22.5 to 33.7).
A comparison of two primary care trials on tennis elbow 1407
www.annrheumdis.com
and injection versus wait and see policy.8 For this analysis,
the physiotherapy group was excluded, as it was only a
treatment option in one of the trials. The main outcome
measures in the two studies were ‘‘pain during the day’’ and
global assessment of change (‘‘improvement’’ versus ‘‘no
improvement’’) at a six week follow up.
Multiple regression (linear regression for pain during the
day, and logistic regression for global assessment of change),
including the treatment6 study interaction was used to test
the differences in treatment outcome across study popula-
tions. If the interaction was not statistically significant,
suggesting that the treatment effect was consistent across the
two study populations, the interaction term was dropped and
differences in treatment outcome were studied in the
combined dataset.
In addition, in order to estimate and compare the overall
effectiveness of the interventions during the one year follow
up, the area under the curve (AUC) for ‘‘pain during the day’’
was calculated.
RESULTS
Study population
In all, 182 patients had consulted the participating general
practices (n=23) in the UK and 164 (90.1%) had finally been
enrolled in the trial. Reasons for exclusion were: no informed
consent (n=12), exclusion criteria (n=5), and inclusion
criteria (n=1). In the study of Smidt et al, 185 (71.4%) of 259
patients consulting participating GPs (n=85) in the
Netherlands were finally included in the trial. Reasons for
exclusion were: no informed consent (n=17), exclusion
criteria (n=52), and inclusion criteria (n=5).
Table 1 shows the demographic and clinical characteristics
and measurements for the two studies at baseline. The study
populations were similar with respect to age, sex, and
comorbid neck and shoulder complaints. Mean age of the
patients in both studies was 48 years and almost 50% of the
study population were female.
However, significant differences were observed for employ-
ment status, duration of elbow complaints, proportion of
patients with the dominant side affected, previous history of
elbow complaints, and use of analgesics. Also, the patients’
attributed causes of their elbow complaints were less often
identified in the study by Hay et al.7
With respect to sociodemographic and clinical character-
istics, the mean severity of pain at baseline was similar in the
two study populations, but self reported disability was greater
among participants in the study by Hay et al.7 By contrast,
severity of the main complaint, severity of the inconvenience
of elbow complaints, and the pain-free grip strength were
significantly worse in the study by Smidt et al.8 There was
little change in these baseline measures after controlling for
differences in sociodemographic and clinical characteristics
(table 1).
Figure 1 presents the course of ‘‘severity of pain during the
day’’ for each intervention, except the physiotherapy treat-
ment. After 12 months of follow up, a decrease in pain during
the day was found for almost all patients (89%), regardless of
their treatment. The course of patients who received a
corticosteroid injection (n=115) was remarkably similar in
the two studies. After one month a large decrease in pain was
found for patients treated with a corticosteroid injection.
Many of these patients reported relapses or recurrences after
six and 12 months of follow up. The course of pain during the
day in patients who received NSAIDs, placebo tablets, and a
wait and see policy was also quite similar (fig 1).
Overall at six weeks, there was improvement in 106 (65%)
of 164 patients in the UK and 158 (85%) of 185 patients in
the Netherlands. Also, for the pooled database, there was an
improvement in 110 (96%) of 115 patients given an injection
and 101 (59%) of 170 patients not given an injection.
Regression analysis using the pooled databases indicated no
significant interaction effect between treatment and study for
both outcome measures (pain during the day and global
assessment of change) (p.0.05). A greater proportion of the
Dutch study population than of the UK population showed
improvement by six weeks (adjusted odds ratio (OR) (95%
confidence interval (CI))=2.8 (1.4 to 5.4)), and less self
reported pain (adjusted mean difference for pain during the
day =7.3 (1.6 to 13.0)).
The area under the curve (AUC) for the injection group
(n=115) and no injection group (without physiotherapy)
showed no significant differences between the studies,
although the AUCs were lower (more pain relief) in
Smidt’s than in Hay’s study (mean difference in AUC (95%
CI) for the injection group=101 (2284 to 487); mean
difference in AUC for the no-injection group=115 (2188 to
419)].
DISCUSSION
The comparison of baseline patient characteristics between
two randomised controlled trials recruiting patients with
lateral epicondylalgia from primary care in different countries
suggests that there are clinical differences between the study
populations. However, the influence of the clinical hetero-
geneity between the studies on the effectiveness of con-
servative treatments for lateral epicondylalgia seems to be
low, as the effectiveness of steroid injections and treatment
with NSAID, placebo tablets, or a wait and see policy were
similar in the two trials. There was a remarkable similarity
between the course of pain in patients who received an
injection in both studies. We do not know the reason for the
high rate of relapses or recurrences in patients who received a
steroid injection. For example, could it be that a steroid
injection is actually harmful in the long term in patients with
a non-inflammatory condition such as lateral epicondylalgia?
Alternatively, do patients overtax their elbow too quickly
after the initial dramatic reduction in pain following an
injection?
The differences between the two studies in the duration of
the elbow complaints and previous episodes of elbow
complaints could be directly explained by disparities in the
defined selection criteria of the two studies. Smidt et al8
excluded recent onset episodes (less than six weeks) and this
was reflected in the longer average duration of elbow
complaints in their study. In contrast, Hay et al7 excluded
patients who had episodes of elbow complaints in the
previous year, resulting in a lower prevalence of past elbow
complaints in their study population.
Figure 1 The severity of pain during the day at baseline and during
follow up at 1, 6, and 12 months after randomisation for each
intervention separately.
1408 Smidt, Lewis, Hay, et al
www.annrheumdis.com
Furthermore, outcome measures used in both studies used
different scales, which might explain the large differences in
grip strength and elbow disability at baseline. The severity of
pain during the day was the only outcome measure at
baseline, which was comparable between the studies. To
facilitate the interpretation and comparison of the results of
various studies on lateral epicondylalgia, additional research
is needed to standardise outcome measures. The incorpora-
tion of a standard set of outcome measures in all future RCTs
on epicondylalgia would greatly enhance comparability of
RCTs.
It is encouraging that recruiting patients from different
countries and health care systems did not affect the
important findings from these trials. Local corticosteroid
injection was effective in the short term for treating lateral
epicondylalgia but, crucially, does not improve long term
outcome. The treatment effects in these two heterogeneous
populations were similar for all interventions examined.
These findings show that these trials have robust external
validity and suggest that their results are generalisable to
other primary care populations of patients with lateral
epicondylalgia.7 8
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